Regulus Therapeutics announced that it has entered into a collaboration with Biogen Idec to identify microRNAs as biomarkers for multiple sclerosis, or MS. Under the transaction, Biogen Idec will make an investment in Regulus in addition to upfront and milestone payments. The key objective of the collaboration is to identify microRNA biomarkers in the blood of patients with MS. Regulus believes that microRNA biomarkers may be used to select optimal patient segments in clinical trials, to develop companion diagnostics, and to monitor disease progression or relapse. Regulus is using a mature therapeutic platform based on technology that has been developed over 20 years. The company works with a broad network of academic collaborators and leverages the oligonucleotide drug discovery and development expertise of its founding companies, Alnylam Pharmaceuticals (ALNY) and Isis Pharmaceuticals (ISIS).
- Biogen Idec
- multiple sclerosis